BioSpace News Archive

Bicara Therapeutics will present positive interim data from its ongoing, open-label Phase 1/1b dose expansion study of BCA101, a first-in-class bifunctional EGFR/TGF-β antibody, at the 2023 American Society of Clinical Oncology Annual Meeting.

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that the Company will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023, at 11:20 a.m. PT in Dana Point, CA.

Immodulon, a late-stage clinical company developing a highly differentiated cancer immunotherapy that primes the patient’s own innate immune system, announces it has appointed Dr Josefine Roemmler-Zehrer, Associate Professor as Chief Medical Officer.

Synlogic, Inc. announced the initiation of Synpheny-3, a global, pivotal Phase 3 study evaluating the efficacy and safety of SYNB1934 as a potential treatment for phenylketonuria.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced it has completed enrollment in the Phase 2 PAVIA clinical trial evaluating EYP-1901 as a potential nine-month treatment for moderate to severe non-proliferative diabetic retinopathy (NPDR).

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that management will participate in two upcoming investor conferences.

Prenetics Global Limited, a leading genomics and precision oncology company, announced financial results for the first quarter ended March 31, 2023, along with recent business updates.

Ractigen Therapeutics, a biopharmaceutical company focused on the discovery, development, and commercialization of novel oligonucleotide therapeutics, announced the dosing of its first patient in the Company’s First in Human clinical trial for ALS patients with SOD1 mutation.

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”) today announced statistically significant and clinically meaningful topline results from the Phase 2b dose-finding trial of obicetrapib, the company’s oral, low-dose and once-daily cholesteryl ester transfer protein (“CETP”) inhibitor, as an adjunct to stable statin therapy in Japanese patients with dyslipidemia.

Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has successfully completed dosing of the third and planned final cohort in its escalating dose Phase 1 clinical study of an intravenous (IV) formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”).